The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)
The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)
批准号:
10408661
负责人:
EBBING LAUTENBACH
金额:
$75.57万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-01 至 2024-05-31
关键词:
AddressAdoptedAntibiotic TherapyAntibioticsCase-Control StudiesCharacteristicsChronicClinicalClinical DataClinical ManagementCohort StudiesColistinCombined AntibioticsComplexComputerized Medical RecordCritical IllnessDataDevelopmentDrug resistanceEnterobacteriaceae InfectionsEpidemiologyEvolutionGenesGeographic LocationsGeographyHigh PrevalenceHospitalsInfectionInfection preventionKnowledgeLength of StayLinkMechanical ventilationMediatingMolecular EpidemiologyMorbidity - disease rateNew AgentsOrganismOutcomePatient-Focused OutcomesPatientsPatternPlasmidsPlayPolymyxinsPopulationPrevalencePublic HealthRegimenReportingResearchResearch ProposalsRiskRisk FactorsRoleSample SizeSentinelSeriesSystemTherapeuticTherapeutic AgentsUnited StatesUnited States Centers for Medicare and Medicaid Servicesacute careantimicrobialcarbapenem resistancecarbapenem-resistant Enterobacteriaceaeclinical careclinical epidemiologyclinical research sitecolistin resistancedrug resistant pathogeneffective therapygenome sequencinghealth care settingshigh riskhospital patient carehospital readmissionimplantable deviceimprovedindividual patientinsightinterdisciplinary approachmortalitypatient populationprimary outcomeprospectiveresistance mechanismresistant Klebsiella pneumoniaetransmission processwhole genome
中文摘要
项目摘要
耐碳青霉烯类肠杆菌科细菌(CRE)的出现和迅速传播是一种主要的
公共卫生威胁。由于CRE引起的感染与显著的发病率和死亡率有关,部分原因是
抗生素治疗选择有限。多粘菌素,包括粘菌素,是重要的最后治疗药物。
CRE感染剂,包括作为可能降低死亡率的联合抗生素方案的一部分。
然而,对粘菌素耐药的CRE(ColR-CRE)病例最近在世界范围内被报道,并代表了一种
主要的治疗挑战,因为目前还没有经过充分研究的治疗方案。急性后护理环境,
特别是长期急性护理医院(LTACH),是越来越重要的临床护理场所
美国。LTACH,由医疗保险和医疗补助服务中心(CMS)定义为
急性护理医院的平均住院时间为≥25天,其特点是慢性危重病人
抗生素暴露率、留置装置使用率和机械通气率高的人群。这些
这些特征显著增加了在该人群中定居和感染Colr-Cre的风险。
由于复杂的、高风险的转移从
将多家急救医院合并到一家机构。由于所有这些原因,LTACH很可能在
Col-Cre的发生和传播。然而,关于临床和临床的数据仍然非常缺乏。
在LTACH环境中特异性COR-CRE的分子流行病学。本提案通过了一项
跨学科方法,并将把Colr-CRE的临床和分子流行病学与实质上联系起来
在LTACH环境中提高对这种高度耐药病原体的理解。的具体目标
这项建议包括以下内容:目标1:确定在中国定居或感染柯尔-卡介苗的危险因素
目的2:评估Colr-Cre定植或感染对长寿期脑出血患者死亡率的影响。
LTACH环境;目标3:使用全基因组测序来前瞻性地评估来自
慢性阻塞性肺病基线患病率较高的长期致死性环芳烃区域网络。拟议研究的完成情况
AIMS将为克雷斯汀耐药的临床和分子流行病学研究提供重要的见解。
医疗保健环境日益重要。阐明Colr-CRE的流行病学将具有重要意义
告知制定有效的感染预防和抗生素管理战略,以限制
这些生物的出现和传播。此外,更广泛地了解流行性感冒的流行病学
LTACH中的Colr-CRE对于降低高度连接的短期和长期网络中的Colr-CRE比率至关重要
术语急性护理环境,包括了解LTACH作为哨兵设施的作用
科尔-克雷。
英文摘要
Project Summary
The emergence and rapid spread of carbapenem-resistant Enterobacteriaceae (CRE) represents a major
public health threat. Infections due to CRE are associated with significant morbidity and mortality, due in part to
limited antibiotic treatment options. The polymyxins, including colistin, are important last-line therapeutic
agents for CRE infections, including as part of combination antibiotic regimens that may reduce mortality.
However, cases of colistin-resistant CRE (colR-CRE) have been recently reported worldwide, and represent a
major therapeutic challenge, as there are no well-studied treatment options available. Post-acute care settings,
and long-term acute care hospitals (LTACHs) in particular, are increasingly important sites of clinical care in
the United States. LTACHs, which are defined by the Centers for Medicare and Medicaid Services (CMS) as
acute care hospitals with an average length of stay of ≥25 days, are characterized by a chronically, critically-ill
population with high rates of antibiotic exposure, indwelling device use, and mechanical ventilation. These
characteristics significantly increase the risk of colonization and infection with colR-CRE in this population.
Rates of colR-CRE are also amplified in LTACHs due to the convergence of complex, high-risk transfers from
multiple acute care hospitals to a single facility. For all of these reasons, LTACHs are likely to be critical in the
emergence and transmission of colR-CRE. However, there is a significant lack of data on the clinical and
molecular epidemiology of colR-CRE specifically in the LTACH setting. This proposal adopts an
interdisciplinary approach, and will link the clinical and molecular epidemiology of colR-CRE to substantially
improve the understanding of this highly drug-resistant pathogen in the LTACH setting. The Specific Aims of
this proposal include the following: Aim 1: To identify risk factors for colonization or infection with colR-CRE in
LTACH patients; Aim 2: To evaluate the impact of colR-CRE colonization or infection on mortality in the
LTACH setting; Aim 3: To use whole-genome sequencing to prospectively evaluate colR-CRE isolates from a
regional network of LTACHs with a high baseline prevalence of CRE. The completion of the proposed research
aims will provide critical insights into the clinical and molecular epidemiology of colistin resistance in CRE in a
healthcare setting of increasing importance. Elucidation of the epidemiology of colR-CRE will significantly
inform the development of effective infection prevention and antibiotic stewardship strategies to limit the
emergence and transmission of these organisms. In addition, a broader understanding of the epidemiology of
colR-CRE in LTACHs is critical for reducing rates of colR-CRE across highly connected short-term and long-
term acute care settings, including understanding the role of LTACHs as sentinel facilities for the emergence of
colR-CRE.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:10649555
-
项目类别:
-
资助金额:$162.73万
-
财政年份:2021
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:10466714
-
项目类别:
-
资助金额:$109.29万
-
财政年份:2021
-
负责人:EBBING LAUTENBACH
-
依托单位:
The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)
-
批准号:9934119
-
项目类别:
-
资助金额:$76.85万
-
财政年份:2018
-
负责人:EBBING LAUTENBACH
-
依托单位:
The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)
-
批准号:10642805
-
项目类别:
-
资助金额:$74.6万
-
财政年份:2018
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:10192602
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2016
-
负责人:EBBING LAUTENBACH
-
依托单位:
Comparative and Cost Effectiveness of Strategies to Limit MRSA in Long Term Care
-
批准号:9340119
-
项目类别:
-
资助金额:$49.39万
-
财政年份:2015
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:9043126
-
项目类别:
-
资助金额:$80.0万
-
财政年份:2015
-
负责人:EBBING LAUTENBACH
-
依托单位:
Urinary Infections due to Escherichia Coli with Reduced Quinolone Susceptibility
-
批准号:8582191
-
项目类别:
-
资助金额:$15.04万
-
财政年份:2013
-
负责人:EBBING LAUTENBACH
-
依托单位:
Urinary Infections due to Escherichia Coli with Reduced Quinolone Susceptibility
-
批准号:8724334
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2013
-
负责人:EBBING LAUTENBACH
-
依托单位:
Development of an Antibiotic Stewardship Bundle to Improve Antibiotic Prescribing
-
批准号:8516400
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2012
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:8633941
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2011
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:8437087
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2011
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:8155117
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2011
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:8234802
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2011
-
负责人:EBBING LAUTENBACH
-
依托单位:
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network
-
批准号:8815108
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2011
-
负责人:EBBING LAUTENBACH
-
依托单位:
Multi-Drug Resistant Urinary Tract Infections in Ambulatory Settings
-
批准号:8146859
-
项目类别:
-
资助金额:$48.53万
-
财政年份:2010
-
负责人:EBBING LAUTENBACH
-
依托单位:
Multi-Drug Resistant Urinary Tract Infections in Ambulatory Settings
-
批准号:8295943
-
项目类别:
-
资助金额:$49.79万
-
财政年份:2010
-
负责人:EBBING LAUTENBACH
-
依托单位:
Multi-Drug Resistant Urinary Tract Infections in Ambulatory Settings
-
批准号:8054695
-
项目类别:
-
资助金额:$48.97万
-
财政年份:2010
-
负责人:EBBING LAUTENBACH
-
依托单位:
Mentoring and patient-oriented research in antimicrobial resistance
-
批准号:7571802
-
项目类别:
-
资助金额:$17.84万
-
财政年份:2009
-
负责人:EBBING LAUTENBACH
-
依托单位:
Mentoring and patient-oriented research in antimicrobial resistance
-
批准号:8415792
-
项目类别:
-
资助金额:$15.34万
-
财政年份:2009
-
负责人:EBBING LAUTENBACH
-
依托单位:
海外基金